Background and Aim: For appropriate management of acute kidney injury (AKI) in cirrhotic patients, accurate differentiation of the types of AKI, prerenal azotemia (PRA), hepatorenal syndrome (HRS), and acute tubular necrosis (ATN) is very important. Urine N-acetyl-β-D-glucosaminidase (NAG) has been proposed as a good tubular injury marker in many studies, but its efficacy in cirrhosis is unclear. This study was performed to evaluate the usefulness of urine NAG in patients with decompensated cirrhosis. Methods: In 114 hospitalized patients with decompensated cirrhosis, we assessed serum creatinine, cystatin C, and urine NAG levels as markers for AKI differentiation and development and patient mortality. Results: Thirty patients diagnosed with AKI at baseline had significantly higher serum creatinine and cystatin C levels, urine NAG levels, and Child-Pugh scores than those without AKI. Only urine NAG levels were significantly higher in patients with ATN than those with PRA or HRS (116.1 ± 46.8 U/g vs 39.4 ± 20.2 or 54.0 ± 19.2 U/g urinary creatinine, all P < 0.05). During a median follow up of 6.1 months, AKI developed in 17 of 84 patients: PRA in nine, HRS in six, and ATN in three. Higher serum cystatin C and urine NAG levels were independent predictors of AKI development in patients with decompensated cirrhosis. Survival was significantly associated with low serum cystatin C and urine NAG levels. Conclusion: Serum cystatin C and urine NAG levels are useful to differentiate types of AKI and are strong predictors for AKI development and mortality in patients with decompensated cirrhosis.
Introduction
Acute kidney injury (AKI) is a common complication of liver cirrhosis and occurs in 20À30% of hospitalized patients with decompensated cirrhosis. [1] [2] [3] It increases the development of complications including variceal bleeding, spontaneous bacterial peritonitis, and encephalopathy by 1.2À1.5 times. 4 Moreover, it is a major cause of death in patients with decompensated cirrhosis. 3, 5 There are several reasons for the high incidence of AKI in patients with cirrhosis. First, compensatory reactions to portal hypertension, including excessive splanchnic vasodilatation and abnormal acceleration of the vasoconstrictor system, reduce effective arterial volume and renal blood flow, ultimately inducing renal impairment. 6 In addition, diuretics overdose, frequent exposure to contrast media used for hepatocellular carcinoma surveillance, and repeated large volume paracentesis for management of refractory ascites could also induce hemodynamic instability and nephrotoxicity. 3, 7, 8 AKIs in cirrhotic patients have traditionally been classified into three types: prerenal azotemia (PRA), hepatorenal syndrome (HRS), and acute tubular necrosis (ATN). Different therapeutic approaches are needed according to the type of AKI: PRA is resolved by supplementing sufficient effective volume, whereas aggressive fluid therapy may cause deterioration in ATN. 4, 6, 9 Intravenous vasopressor plus albumin or liver transplantation is needed in patients with HRS.
The International Ascites Club (IAC) has revised the IAC-AKI criteria, according to which the serum creatinine (Cr) levels should have increased by ≥0.3 mg/dL within 48 h or by ≥50% within 7 days. This has allowed the earlier diagnosis of AKI. 6 However, to date, it remains challenging to differentiate AKI types, which delays appropriate treatment. Kidney biopsy is the gold standard, 8 but it is not performed regularly in clinical practice because it is time-consuming and involves complications such as pain, bleeding, and additional kidney injury. Even if HRS and ATN are suspected due to patient unresponsiveness to fluid therapy, the distinction between the two types by clinical features is not easy due to the common use of diuretics in cirrhotic patients.
To resolve this problem, several studies on cirrhosis using biomarkers have been conducted. [9] [10] [11] [12] They have reported that urine neutrophil gelatinase-associated lipocalin (NGAL) is significantly increased in cirrhotic patients with ATN compared with those with PRA or HRS. However, urine NGAL levels are also elevated in conditions that stimulate epithelial cells such as sepsis, malignant tumor, and chronic obstructive pulmonary disease, which can lead to false positives. 13 In addition, there is significant overlap in NGAL levels between ATN and HRS, making it difficult to clearly distinguish between them. 9, 10, 14 Among previously reported kidney biomarkers, serum cystatin C is an endogenous inhibitor of cysteine proteinases. 15 Because of its non-adherence to plasma proteins and low molecular weight, it is freely filtered by the glomeruli and subsequently reabsorbed and catabolized in the proximal tubular cells. 15, 16 Unlike serum Cr, serum cystatin C is not affected by age, sex, muscle amount, bilirubin levels, inflammation, or malignancy. 6, 17, 18 Therefore, serum cystatin C has become a potent marker for renal function in patients with cirrhosis, 18, 19 and it has a high predictive accuracy for the development of AKI and mortality in these patients. 19, 20 On the other hand, urine N-acetyl-β-D-glucosaminidase (NAG) is a lysosomal enzyme present predominantly in proximal tubules. It has too high a molecular weight (140 kDa) to penetrate the glomerular basal membrane; therefore, it cannot increased by non-renal sources. 21 In many studies, it was shown to be a sensitive marker for renal tubular damage. [22] [23] [24] [25] Moreover, it was increased earlier than serum Cr in patients with AKI, [26] [27] [28] which made it possible to diagnose AKI more quickly. However, no study to date has applied urine NAG in patients with cirrhosis.
Thus, the present study aimed to evaluate the efficacy of two kidney biomarkers, serum cystatin C and urine NAG, for the differentiation of the type of AKI and prediction of prognosis in patients with decompensated cirrhosis.
Methods
Study design. Patients with decompensated cirrhosis admitted to our hospital and tested for serum cystatin C and urine NAG levels between September 2016 and August 2017 were included. Patients with chronic kidney disease or coexisting malignancy, such as hepatocellular carcinoma, were excluded. Liver cirrhosis was diagnosed based on histology and/or laboratory and imaging studies, and decompensation was defined as a Child-Pugh score ≥7. The retrospective study protocol conformed to the ethical guidelines of the 1975 Helsinki Declaration and was approved by our institutional review board. A waiver of informed consent was obtained, and patient records were anonymized and de-identified before analysis.
Acute kidney injury was diagnosed as acute increase in serum Cr levels by ≥0.3 mg/dL in less than 48 h or 50% increase in serum Cr levels from baseline. 6 The definitions used for AKI types were as follows: PRA was diagnosed when patients experienced fluid losses, including bleeding and diuretic overdose, in the preceding days, together with compatible findings, absence of other causes of impairment of kidney function, and reversibility of renal impairment as indicated by a return of serum Cr to within 25% of baseline within 48 h after fluid resuscitation. 9 HRS was defined using the current definition of IAC-AKI. 29 ATN was diagnosed in patients with at least three of the following: hypovolemic and/or septic shock or treatment with potentially nephrotoxic agents, urine sodium ≥40 mEq/L, urine osmolality ≤400 mOsm/kg, and FENa ≥2% without diuretics. 30, 31 Data collection. Patient data including age, sex, and underlying liver disease (chronic hepatitis B, chronic hepatitis C, alcoholic liver disease, and others) were collected during hospitalization. Results of laboratory tests (platelet count, international normalized ratio, serum alanine aminotransferase, bilirubin, albumin, electrolytes, osmolality, and consecutive Cr levels; NAG, electrolyte, osmolality, Cr levels in urine) were collected at enrollment. Serum cystatin C assay was performed using latex-particle-enhanced turbidimetric immunoassay (Dako, Glostrup, Denmark) on a CX7 analyzer (Beckman, CA, USA). Urine NAG was measured by a colorimetric assay (CicaFit, Kanto, Japan). Child-Pugh scores were determined by applying Pugh's commonly used modification, which is based on the presence and severity of ascites and hepatic encephalopathy, prothrombin time prolongation, and serum bilirubin and albumin levels. 32 Statistics. Statistical analyses were performed using SPSS software version 20.0 (SPSS Inc., Chicago, IL, USA). Data are expressed as mean ± standard deviation or number (%). Student's t-test and Mann-Whitney U-test were used to compare continuous variables, and the chi-squared test and Fisher's exact test were used to compare categorical variables. The area under the receiver operating characteristic curve (AUC) with 95% confidence intervals (CI) was calculated to evaluate the predictive accuracy of biomarkers for the development of AKI. Significant factors associated with presence of baseline AKI type were analyzed using binary logistic regression analysis. The cumulative incidences of AKI and mortality were calculated by Kaplan-Meier plots, and differences between groups were assessed by the log-rank test. A Cox proportion hazard regression model was performed to analyze factors associated with mortality and AKI development; significant factors in the univariate analysis were subjected to multivariate analysis to determine independent predictive factors. All tests were two-tailed, and P values <0.05 were considered statistically significant.
Results
Baseline characteristics. The patients' characteristics are presented in Table 1 . Mean age was 58.6 ± 12.4 years, and 81 patients (71.1%) were men. Alcoholic liver disease was the most frequent underlying liver disease (76 patients, 66.7%), followed by chronic hepatitis B (19 patients, 16.7%). Serum Cr and cystatin C levels were 1.2 ± 0.8 mg/dL and 1.3 ± 0.7 mg/L, respectively. Mean urine NAG levels were 39.3 ± 37.9 U/g urinary Cr. The Child-Pugh score was 10.4 ± 2.2.
Acute kidney injury was present in 30 patients (26.3%) at baseline. Serum Cr and cystatin C levels, urine NAG levels, and Child-Pugh scores were significantly higher in patients with AKI at baseline than in those without, while serum sodium levels were significantly lower in patients with AKI at baseline than in those without ( Table 1 ). The use of diuretics did not significantly affect levels of serum cystatin C and urine NAG (Table S1 ).
Biomarkers according to acute kidney injury type at baseline. Acute kidney injury type at baseline was PRA in 19 patients (16.7%), ATN in seven (6.1%), and HRS in four (3.5%). Serum Cr levels in patients without AKI (0.9 ± 0.3 mg/ dL) were significantly lower than in patients with PRA (1.8 ± 0.7 mg/dL, P < 0.001), ATN (2.3 ± 1.6 mg/dL, P < 0.001), and HRS (2.2 ± 0.7 mg/dL, P < 0.001). However, they did not differ significantly between patients with PRA and those with ATN (P = 0.185) or HRS (P = 0.731) and between patients with ATN and those with HRS (P = 0.953) (Fig. 1a) . Serum cystatin C levels in patients without AKI were significantly lower than in patients with PRA (1.8 ± 0.8 mg/L, P < 0.001), ATN (2.2 ± 1.0 mg/L, P < 0.001), and HRS (2.4 ± 0.6 mg/L, P < 0.006). However, they did not differ significantly between patients with PRA and those with ATN (P = 0.530) or HRS (P = 0.350) and between patients with ATN and those with HRS (P = 0.959) (Fig. 1b) . Urine NAG levels in patients with ATN (116.1 ± 46.8 U/g urinary Cr) were significantly higher than in patients without AKI (32.2 ± 33.6 U/g urinary Cr, P < 0.001), with PRA (39.4 ± 20.2 U/g urinary Cr, P < 0.001), and with HRS (54.0 ± 19.2 U/g urinary Cr, P = 0.015), while they did not differ significantly between patients without AKI and those with PRA (P = 0.822) or HRS (P = 0.559) and between patients with PRA and those with HRS (P = 0.846) (Fig. 1c) . A cut-off value of 53.2 U/g urinary Cr differentiated ATN from HRS with 100% sensitivity and 75.0% specificity.
Development of acute kidney injury during follow up. For 84 patients without AKI at baseline, AKI developed in 17 patients during a median follow-up period of 6.1 months (PRA in nine, ATN in six, and HRS in three). The cumulative incidences of AKI at 3, 6, 9, and 12 months were 16.3%, 20.2%, 22.7%, and 26.8%, respectively. In univariate Cox regression analysis, serum Cr, cystatin C, and sodium levels, urine NAG levels, and Child-Pugh scores were significantly associated with the development of AKI. In multivariate analysis, serum cystatin C levels and urine NAG levels were independent predictors of the development of AKI (Table 2) .
In AUC analysis for predicting the development of AKI within 6 months, values of serum Cr, cystatin C, and urine NAG were 0.562 (95% CI, 0.381-0.743), 0.802 (95% CI, 0.683-0.921), and 0.833 (95% CI, 0.715-0.952), respectively (Fig. 2) . The optimal cut-off values for the levels of serum cystatin C and urine NAG were 1.0 mg/L (sensitivity, 80.0%; specificity, 72.5%) and 31.0 U/g urinary Cr (sensitivity, 86.7%; specificity, 77.5%), respectively. Using these, patients were classified into three groups as follows: group 1, patients with serum cystatin C <1.0 mg/L and urine NAG <31 U/g urinary Cr (n = 41); group 2, patients with serum cystatin C ≥1.0 mg/L and urine NAG <31 U/g urinary Cr, or those with serum cystatin C <1.0 mg/L and urine NAG ≥31 U/g urinary Cr (n = 31); and group 3, patients with serum cystatin C ≥1.0 mg/L and urine NAG ≥31 U/g urinary Cr (n = 12).
The incidence of AKI was significantly different by serum cystatin C and urine NAG levels (Fig. 3) . The incidences of AKI at 3, 6, 9, and 12 months were 0%, 0%, 5.9%, and 5.9%, respectively, in group 1; 11.6%, 19.1%, 19.1%, and 27.2%, respectively, in group 2; 87.5%, 87.5%, 87.5%, and 87.5%, respectively, in group 3 (P < 0.001).
Survival. During follow up, 21 patients died. The causes were liver failure in 10 patients, infection in five, variceal bleeding in four, and others in two. The cumulative survival rates at 3, 6, 9, and 12 months were 82.9%, 82.9%, 80.3%, and 77.0%, respectively. Serum Cr, cystatin C, sodium levels, urine NAG levels, and Child-Pugh scores were significantly associated with mortality in univariate Cox regression analysis. In multivariate analysis, serum cystatin C levels, urine NAG levels, and Child-Pugh scores were independent predictors of mortality (Table 3) . Survival rates differed significantly by serum cystatin C and urine NAG levels (P < 0.001) (Fig. 4) . The survival rates at 3, 6, 9, and 12 months were 95.1%, 95.1%, 95.1%, and 95.1%, respectively, in group 1; 87.7%, 87.7%, 87.7%, and 80.4%, respectively, in group 2; 56.6%, 56.6%, 45.3%, and 45.3%, respectively, in group 3.
Discussion
Acute kidney injury is a common complication in patients with cirrhosis, especially in those with decompensation. Although serum Cr level is the most widely used marker of renal function, its usefulness have been debated in patients with liver cirrhosis because of the reduction of muscle mass and increased renal tubular excretion of Cr. [33] [34] [35] [36] While, especially in cirrhosis, it is important to distinguish between HRS and ATN because HRS must be treated with vasoconstrictors and albumin, while ATN should generally be treated with renal replacement therapy. 37 Therefore, this study evaluated the usefulness of serum cystatin C and urine NAG levels (to our knowledge, the first study on the latter) for the differentiation of the type of AKI and for prediction of the development of AKI in patients with decompensated cirrhosis.
In this study, although baseline serum Cr and cystatin C levels and urine NAG level were useful for distinguishing between AKI and non-AKI states, only urine NAG was helpful for the differentiation between ATN and PRA or HRS in patients with decompensated cirrhosis. These results demonstrate that urine NAG is a marker specific to renal tubular damage in decompensated cirrhosis. In classifying AKI types, the most obvious method is the histological examination of the kidney. However, biopsy-related complications occurred in 13% of patients without liver disease, and 66% of these complications were hematomas and hematuria. 38 Abnormal coagulation, thrombocytopenia, and ascites, which present more severely in decompensated cirrhosis, limit the availability of kidney biopsy. Indeed, it has not been used and remains challenging in most patients with cirrhosis. Considering the results of this study, serum cystatin C and urine NAG could be alternatives for distinguishing AKI types without critical complications.
Furthermore, serum cystatin C and urine NAG levels were very useful for predicting the development of AKI in patients with decompensated cirrhosis. AUCs for predicting the development of AKI within 6 months were 0.802 and 0.833 for serum cystatin C and urine NAG, respectively. The incidence of AKI was significantly associated with serum cystatin C and urine NAG levels. Moreover, the development of AKI during follow up was significantly related to only serum cystatin C and urine NAG levels as independent predictors. These also showed superiority to serum Cr for predicting the development of AKI. Similarly, several previous studies have suggested that urine NAG levels are useful for predicting AKI development in non-cirrhotic patients. In a previous study, urine NAG was significantly different between patients with AKI and without in the intensive care unit (27.4 vs 99.0 U/g urinary Cr, P < 0.05). 27 The AUC of urine NAG showed excellent discriminating power for AKI development (0.845; 95% CI, 0.639-0.955) and with a cut-off of 73.4 U/g urinary Cr; the Assessment of acute kidney injury in decompensated cirrhosis sensitivity and specificity for AKI development were 75.0% and 75.0%, respectively. 27 In another study, the AUC of urine NAG for postoperative AKI in patients who had undergone cardiac surgery was 0.61 (95% CI, 0.50-0.71), and at a cut-off of 25.0 U/g urinary Cr, the sensitivity and specificity for postoperative AKI were 74.3% and 50.0%, respectively. 28 Although the diagnostic criteria for AKI, characteristics and number of subjects, and observation period were different, the efficacy of urine NAG for predicting AKI development in this study is comparable or superior with those of previous studies. Thus, this study proved that urine NAG remains a good predictive marker for AKI in patients with decompensated cirrhosis as well as those without liver disease. Figure 3 Kaplan-Meier plots for development of AKI in patients with decompensated cirrhosis without AKI at baseline. Group 1, patients with serum cystatin C levels <1.0 mg/L and urine NAG levels <31 U/g urinary Cr; group 2, patients with serum cystatin C levels ≥1.0 mg/L and urine NAG levels <31 U/g urinary Cr or those with serum cystatin C levels <1.0 mg/L and urine NAG levels ≥31 U/g urinary Cr; and group 3, patients with serum cystatin C levels ≥1.0 mg/L and urine NAG levels ≥31 U/g urinary Cr. AKI, acute kidney injury; Pts, patients. [Color figure can be viewed at wileyonlinelibrary.com] Assessment of acute kidney injury in decompensated cirrhosis TH Kim et al.
For predicting mortality, serum cystatin C and urine NAG levels played the role of independent predictors with Child-Pugh scores. In addition, patients with high serum cystatin C and urine NAG levels (group 3) showed significantly increased mortality and AKI development compared with those in the other groups. In addition, HRS developed only in these patients. These results demonstrate that both serum cystatin C and urine NAG levels act as prognostic markers for patients with decompensated cirrhosis. Meanwhile, those also indicate that decreased renal blood flow accompanied by tubular injury synergistically accelerate the development of complications and aggravate the prognosis of decompensated cirrhosis.
There are some limitations to this study. First, because this study was retrospective, selection bias could occur even though we attempted to measure serum cystatin C and urine NAG in all hospitalized patients with decompensated cirrhosis. Second, the number of patients and events was relatively small to conduct further subgroup analysis. Third, NGAL, which was evaluated in most previous studies, was not measured in this study. Therefore, the efficacy of NGAL was not investigated in this study. Despite these limitations, the present study is the first to explore the efficacy of urine NAG in decompensated cirrhosis.
Applying our findings to clinical practice, high urine NAG levels in the AKI state would be helpful for distinguishing ATN from other types of AKI, allowing appropriate early treatment. Considering transplantation a therapy, determination of urine NAG levels could also assist in avoiding unnecessary simultaneous liver kidney transplants. With high values of both serum cystatin C and urine NAG in the non-AKI state, close follow up and avoidance of precipitating factors, such as hypovolemia, nephrotoxic agents, and infection, must be required.
In conclusion, urine NAG performed well as a tubular injury marker and independent prognostic predictor in patients with decompensated cirrhosis. In addition, the use of urine NAG in conjunction with cystatin C may provide more accurate predictions for development of AKI and mortality. Prospective studies including more patients and biomarkers are warranted for future clinical applications. AKI, acute kidney injury; ATN, acute tubular necrosis; ALT, alanine aminotransferase; BMI, body mass index; CI, confidence interval; Cr, creatinine; HR, hazard ratio; HTN, hypertension; INR, international normalized ratio; Na, serum sodium; NAG, N-acetyl-β-D-glucosaminidase. Figure 4 Kaplan-Meier plots for mortality of groups according to serum cystatin C and urine NAG levels. Group 1, patients with serum cystatin C levels <1.0 mg/L and urine NAG levels <31 U/g urinary Cr; group 2, patients with serum cystatin C levels ≥1.0 mg/L and urine NAG levels <31 U/g urinary Cr or those with serum cystatin C levels <1.0 mg/L and urine NAG levels ≥31 U/g urinary Cr; and group 3, patients with serum cystatin C levels ≥1.0 mg/L and urine NAG levels ≥31 U/g urinary Cr. LT, liver transplantation; Pts, patients. [Color figure can be viewed at wileyonlinelibrary.com]
